Allergy, Asthma & Respiratory Disease

The Korean Academy of Asthma, Allergy and Clinical Immunology (대한천식알레르기학회)
권호 표지
DOI QR코드

DOI QR Code

Head-to-head comparison between subcutaneous and sublingual immunotherapy in perennial allergic rhinitis: A systematic review and meta-analysis

  • Soo Jie Chung (Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital) ;
  • Jin-ah Sim (Department of AI Convergence, Hallym University) ;
  • Hyo-Bin Kim (Department of Pediatrics, Inje University Sanggye Paik Hospital) ;
  • Do-Yang Park (Department of Otolaryngology, Ajou University School of Medicine) ;
  • Jeong-Hee Choi (Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital)
  • Received : 2023.05.26
  • Accepted : 2023.08.23
  • Published : 2024.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Few meta-analyses of head-to-head comparisons between subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) have been performed so far. This study aimed to compare the efficacy, safety, and adherence of SCIT and SLIT in patients with house dust mite (HDM)-sensitized AR through a meta-analysis of head-to-head comparative studies. Methods: A meta-analysis based on direct comparisons of SCIT and SLIT in HDM-sensitized AR was performed, using randomized controlled trials (RCTs) and nonrandomized studies (NRSs), on efficacy, safety, and adherence, which had been published until April 30, 2021. Treatment efficacy was calculated as the standardized mean difference in symptoms and medication scores after treatment between SCIT and SLIT. Safety and adherence to treatment were compared with the relative risk (RR) of SCIT and SLIT. Results: Six RCTs and 3 NRS scores were analyzed. No statistically significant difference was noticed in improvement in symptoms and medication scores between SCIT and SLIT groups. Systemic adverse events occurred more frequently in SCIT than in SLIT in both RCT (RR, 3.97; 95% confidence interval [CI], 0.50-31.57) and NRS (RR, 5.48; 95% CI, 1.94-15.50). SCIT showed significantly higher adherence than did SLIT (RR, 1.16; 95% CI, 0.92-1.47). Conclusion: No significant difference in efficacy was noticed between the 2 modalities for HDM-sensitized AR. However, SLIT had significantly lower number of systemic adverse reactions, and SCIT had more preferable adherence.

Keywords

Acknowledgement

We specially give thanks to all members of Korean Academy of Asthma, Allergy, and Clinical Immunology (KAAACI), the Working Group on Allergic Rhinitis.

References

  1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108(1 Suppl):S2-8.
  2. Dierick BJH, van der Molen T, Flokstra-de Blok BMJ, Muraro A, Postma MJ, Kocks JWH, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res 2020;20:437-53.
  3. Georgy MS, Saltoun CA. Chapter 3: allergen immunotherapy: definition, indication, and reactions. Allergy Asthma Proc 2012;33 Suppl 1:9-11.
  4. Petalas K, Durham SR. Allergen immunotherapy for allergic rhinitis. Rhinology 2013;51:99-110.
  5. Calderon MA, Carr VA, Jacobson M, Sheikh A, Durham S. Allergen injection immunotherapy for perennial allergic rhinitis. Cochrane Database Syst Rev 2019;2019:CD007163.
  6. Huang Y, Wang C, Wang X, Zhang L, Lou H. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: a meta-analysis of randomized controlled trials. Allergy 2019;74:189-92.
  7. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6.
  8. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012;157:288-98.
  9. Xian M, Feng M, Dong Y, Wei N, Su Q, Li J. Changes in CD4+CD25+ FoxP3+ regulatory T cells and serum cytokines in sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma. Int Arch Allergy Immunol 2020;181:71-80.
  10. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45-53.
  11. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:1253-61.
  12. Ventura MT, Carretta A, Tummolo RA, Buquicchio R, Arsieni A, Murgia N. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy. Int J Immunopathol Pharmacol 2009;22:403-13.
  13. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol 2012;130:1097-107.e2.
  14. Kim JY, Jang MJ, Kim DY, Park SW, Han DH. Efficacy of subcutaneous and sublingual immunotherapy for house dust mite allergy: a network meta-analysis-based comparison. J Allergy Clin Immunol Pract 2021;9:4450-8.e6.
  15. Tie K, Miller C, Zanation AM, Ebert CS Jr. Subcutaneous versus sublingual immunotherapy for adults with allergic rhinitis: a systematic review with meta-analyses. Laryngoscope 2022;132:499-508.
  16. Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. J Allergy Clin Immunol Pract 2015;3:256-66.e3.
  17. Incorvaia C, Mauro M, Leo G, Ridolo E. Adherence to sublingual immunotherapy. Curr Allergy Asthma Rep 2016;16:12.
  18. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
  19. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
  20. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2021;12:55-61.
  21. Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirican A. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec 2008;70:144-50.
  22. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010;40:922-32.
  23. Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol 2015;25:334-42.
  24. Wang ZX, Shi H. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis. J Huazhong Univ Sci Technolog Med Sci 2017;37:407-11.
  25. You SH, Qin XY, Xu C, Qiu X, Luan ZL, Jia HX, et al. Comparison study of subcutaneous immunotherapy and sublingual immunotherapy in patients with allergic rhinitis. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016;30:689-93.
  26. Liu W, Zeng Q, He C, Chen R, Tang Y, Yan S, et al. Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis. Pediatr Allergy Immunol 2021;32:86-91.
  27. Zhu L, Lu JH, Xie Q, Wu YL, Zhu LP, Cheng L. [Compliance and safety evaluation of subcutaneous versus sublingual immunotherapy in mite-sensitized patients with allergic rhinitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010;45:444-9. Chinese.
  28. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485-90.
  29. Epstein TG, Calabria C, Cox LS, Dreborg S. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract 2017;5:34-40.e2.
  30. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;2007:CD001936.
  31. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 2016;137:339-49.e10.
  32. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy 2013;43:22-8.